Petosemtamab is projected to reach $1.2bn in global sales by 2030, while ficerafusp alfa will reach $620 million.

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with ...

In patients undergoing chronic total occlusion (CTO) percutaneous coronary intervention (PCI), stenting demonstrated improved ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

At 30 days, 137 of 3030 patients (4.5%) in the intraosseous group and 155 of 3034 (5.1%) in the intravenous group were alive (adjusted odds ratio, 0.94; 95% confidence interval [CI], 0.68 to 1.32 ...

Waist-to-height ratio predicts heart failure incidence, according to research presented today at Heart Failure 2025, a scientific congress of the European Society of Cardiology (ESC).